Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
NewsPartner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MRUS
stocks logo

MRUS

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
8.70M
-26.13%
-1.323
-9.4%
9.64M
+5.45%
-1.257
+156.48%
8.07M
-69.53%
-1.380
-1.43%
Estimates Revision
The market is revising Upward the revenue expectations for Merus N.V. (MRUS) for FY2025, with the revenue forecasts being adjusted by 2.17% over the past three months. During the same period, the stock price has changed by 56.48%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.17%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.62%
In Past 3 Month
Stock Price
Go Up
up Image
+56.48%
In Past 3 Month
13 Analyst Rating
up Image0
Wall Street analysts forecast MRUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRUS is 94.70 USD with a low forecast of 67.00 USD and a high forecast of 110.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
0 Hold
0 Sell
Strong Buy
up Image0
Current: 64.000
sliders
Low
67.00
Averages
94.70
High
110.00
up Image0
Current: 64.000
sliders
Low
67.00
Averages
94.70
High
110.00
BofA
Buy
upgrade
$70 -> $92
2025-05-23
Reason
BofA
Price Target
$70 -> $92
2025-05-23
upgrade
Buy
Reason
BofA raised the firm's price target on Merus to $92 from $70 and keeps a Buy rating on the shares after the company reported 12-month landmark objective survival of 79% in its full phase 2 cohort for petosemtamab plus pembrolizumab. This OS rate compares favorably to the historical 50%-59% benchmark for pembro monotherapy in first-line head and neck squamous cell carcinoma and is also significantly higher than the 50%-60% range the firm's doctor checks had indicated would be "good data," the analyst tells investors. The firm thinks the data sets the "peto'+pembro" combination up to be "the best-in-class treatment option for this patient population," the analyst added.
BMO Capital
Etzer Darout
Outperform
upgrade
$96 -> $110
2025-05-23
Reason
BMO Capital
Etzer Darout
Price Target
$96 -> $110
2025-05-23
upgrade
Outperform
Reason
BMO Capital analyst Etzer Darout raised the firm's price target on Merus to $110 from $96 and keeps an Outperform rating on the shares. The firm notes that ASCO readouts are off to a strong start with the updated Phase 2 data of Merus's petosemtamab + pembro in first-line HNSCC, the analyst tells investors in a research note. BMO adds that it has a higher confidence in the approvability of petosemtamab in HNSCC, with probability of success rising to 90% from 85%.
Wells Fargo
Overweight
downgrade
$91 -> $89
2025-05-08
Reason
Wells Fargo
Price Target
$91 -> $89
2025-05-08
downgrade
Overweight
Reason
Wells Fargo lowered the firm's price target on Merus to $89 from $91 and keeps an Overweight rating on the shares. The firm says there was not much new on the PR as the company continues to execute on its petosemtamab studies. Wells sees the ASCO update in first-line HNSCC and the mCRC update in the second half of 2025 for petosemtamab as the key catalysts in the next 12 months.
Needham
Ami Fadia
Strong Buy
Reiterates
$83
2025-04-09
Reason
Needham
Ami Fadia
Price Target
$83
2025-04-09
Reiterates
Strong Buy
Reason
Guggenheim
Michael Schmidt
Strong Buy
Reiterates
$109
2025-03-28
Reason
Guggenheim
Michael Schmidt
Price Target
$109
2025-03-28
Reiterates
Strong Buy
Reason
Guggenheim
Michael Schmidt
Strong Buy
Reiterates
$109
2025-03-18
Reason
Guggenheim
Michael Schmidt
Price Target
$109
2025-03-18
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Merus NV (MRUS.O) is -13.48, compared to its 5-year average forward P/E of -9.97. For a more detailed relative valuation and DCF analysis to assess Merus NV 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-9.97
Current PE
-13.48
Overvalued PE
-6.57
Undervalued PE
-13.38

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6.03
Current EV/EBITDA
-10.72
Overvalued EV/EBITDA
-2.66
Undervalued EV/EBITDA
-9.40

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Overvalued
5Y Average PS
40.45
Current PS
165.30
Overvalued PS
70.43
Undervalued PS
10.46

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

MRUS News & Events

Events Timeline

(ET)
2025-08-05
16:38:41
Merus sees cash runway at least into 2028
select
2025-08-05
16:38:09
Merus reports Q2 EPS ($2.23), consensus ($1.15)
select
2025-06-04 (ET)
2025-06-04
06:07:23
Merus 5.27M share Spot Secondary priced at $57.00
select
Sign Up For More Events
Sign Up For More Events

News

Preview
4.0
08-06Benzinga
Needham Maintains Buy on Merus, Lowers Price Target to $96

  • Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.

  • Exclusive Community Access: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

Preview
4.0
06-12TipRanks
3 Best Stocks to Buy Now, 6/12/2025, According to Top Analysts

  • Top Stock Picks: Analysts recommend three stocks as Strong Buys: Merus (MRUS) with an 80.93% upside, ACM Research (ACMR) with a 50.87% upside, and Nvidia (NVDA) with a 22.09% upside, all receiving recent Buy ratings from top analysts.

  • Analyst Rankings: TipRanks provides a tool to track real-time stock ratings from top-ranking analysts, highlighting their success rates and average returns, ensuring investors can make informed decisions based on expert insights.

Preview
2.0
06-04Benzinga
CrowdStrike, Asana And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

  • U.S. Stock Market Update: U.S. stock futures showed slight gains, with Dow futures up 0.1%. However, several companies, including CrowdStrike and Asana, experienced significant declines in pre-market trading following disappointing earnings reports.

  • CrowdStrike Earnings Report: Despite better-than-expected first-quarter earnings and an increase in full-year guidance, CrowdStrike's shares fell 7% due to lower than anticipated second-quarter revenue projections and adjusted earnings estimates.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Merus NV (MRUS) stock price today?

The current price of MRUS is 64 USD — it has increased 0.96 % in the last trading day.

arrow icon

What is Merus NV (MRUS)'s business?

Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.

arrow icon

What is the price predicton of MRUS Stock?

Wall Street analysts forecast MRUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRUS is 94.70 USD with a low forecast of 67.00 USD and a high forecast of 110.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Merus NV (MRUS)'s revenue for the last quarter?

Merus NV revenue for the last quarter amounts to 8.83M USD, increased 20.40 % YoY.

arrow icon

What is Merus NV (MRUS)'s earnings per share (EPS) for the last quarter?

Merus NV. EPS for the last quarter amounts to -2.23 USD, increased 175.31 % YoY.

arrow icon

What changes have occurred in the market's expectations for Merus NV (MRUS)'s fundamentals?

The market is revising Upward the revenue expectations for Merus N.V. (MRUS) for FY2025, with the revenue forecasts being adjusted by 2.17% over the past three months. During the same period, the stock price has changed by 56.48%.
arrow icon

How many employees does Merus NV (MRUS). have?

Merus NV (MRUS) has 260 emplpoyees as of August 09 2025.

arrow icon

What is Merus NV (MRUS) market cap?

Today MRUS has the market capitalization of 4.84B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free